News | July 31, 2009

Theregen’s Anginera Patch Used as Foundation for Beating Heart Cell Patch

July 31, 2009 – Theregen Inc. said its Anginera heart patch, a living three-dimensional engineered human tissue, was used as the foundation for the ”living band-aid for the heart,” as reported recently at the 2009 American Heart Association Cardiovascular Sciences Conference in Las Vegas, NV.

Anginera, an epicardial patch containing living human fibroblast cells and extracellular matrix, induces arteriogenesis, repair and restoration of regional heart function. The heart cells embedded in the Anginera tissue scaffold were derived from rat heart tissue. Researchers Steven Goldman, M.D. and Jordan Lancaster, B.S., from the Southern Arizona Veterans Administration and the University of Arizona Sarver Heart Center, reported that the Anginera patch cultured with rat heart cells can beat in coordinated rhythm at various rates

The company said Anginera is currently in human clinical testing for cardiac applications. The patch has demonstrated an ability to stimulate new mature blood vessels (arteriogenesis) in the human heart in trial patients and improve left ventricular function in animal models.

For more information: www.theregen.com

Related Content

FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
Overlay Init